Key Highlights

  • Revenue was USD 164.399 million against USD 138.743 million a year earlier, with organic Revenue up 19.1%.
  • Adjusted diluted EPS was USD 1.07 against an estimate of USD 0.74, while GAAP diluted EPS was USD 0.91.
  • Bookings were USD 218.057 million and Backlog was USD 351.489 million, against USD 133.119 million and USD 230.984 million.
  • Gross Margin was 36.6% against 33.3%, and Adjusted EBITDA was USD 29.652 million against USD 20.299 million.

Allient (NASDAQ:ALNT) gave a short list of full year markers alongside its third quarter results: capital expenditures of USD 12 million to USD 15 million for 2026, an income tax rate of approximately 21% to 23%, and about USD 2 million of total costs for the Dothan, Alabama realignment, with payment substantively complete by the end of 2026, the company said. It did not publish a revenue or Earnings range. Adjusted diluted EPS was USD 1.07 against an estimate of USD 0.74 and USD 0.59 a year earlier.

Guidance Markers and the Simplify to Accelerate NOW Program

The company has been executing its Simplify to Accelerate NOW program through 2024, 2025 and into 2026, covering a Manufacturing footprint realignment and a streamlined organization. Management said additional costs under the program are intended to create more annualized savings in 2026. Assembly operations are moving from Dothan into facilities in Tulsa, Oklahoma and Reynosa, Mexico, with restructuring and Business realignment costs of USD 1.518 million in the nine months, against USD 3.457 million.

Cash and cash equivalents were USD 39.646 million at September 30. Revolving Facility obligations were USD 117.962 million with USD 162.038 million unused, and the facility matures March 1, 2029. The Series A Senior Notes are due March 21, 2031, and the company stated it was in compliance with all covenants.

The Quarter in Detail

Revenue was USD 164.399 million, against USD 138.743 million, which management attributed to a 19.1% Volume increase with a 0.6% negative currency impact. Gross Profit was USD 60.185 million, against USD 46.181 million. Operating Income was USD 22.3 million, against USD 12.18 million, and Net Income was USD 15.325 million, against USD 6.477 million, with an effective tax rate of 22.2% in both periods.

Adjusted net income was USD 18.007 million, against USD 9.885 million, and EBITDA was USD 28.284 million, against USD 18.146 million. Selling expenses rose 19%, general and administrative expenses rose 21% and engineering and development expenses rose 6%. Interest expense was USD 2.494 million, against USD 3.401 million, on lower average debt.

Target Markets and Order Book

Industrial revenue was USD 81.694 million, against USD 71.023 million, and Aerospace and Defense revenue was USD 25.493 million, against USD 18.755 million. Vehicle revenue was USD 27.31 million, against USD 21.584 million, while Medical revenue was USD 21.299 million, against USD 21.656 million. Customers in the United States made up 57% of revenue.

Bookings rose 64.4% on volume, which the company tied to improved Demand in Industrial and Aerospace and Defense. Backlog was USD 351.489 million. For the nine months, revenue was USD 457.084 million, net income was USD 31.073 million and diluted EPS was USD 1.84. Operating Cash Flow was USD 22.084 million, capital expenditures were USD 10.64 million and net Debt payments were USD 7.343 million.

Dates and Milestones Named

Revenue of USD 164.399 million sits alongside adjusted EPS of USD 1.07, backlog of USD 351.489 million and revolver obligations of USD 117.962 million.

Dated items named are the Revolving Facility Maturity on March 1, 2029, the Series A Senior Note maturity on March 21, 2031, and the substantive payment of remaining Dothan realignment costs by the end of 2026. The company declared dividends of USD 0.11 per share in the first nine months, against USD 0.09 a year earlier, and stated that cash from operations and Credit facility availability fund its working capital, Capital Expenditure and Dividend needs.